



PRESS RELEASE

- **ORABLOC® INIETTORE MONOUSO: Pierrel Pharma S.r.l is preparing to launch in Poland a unique device in the world, destined for dental anaesthetics, with total safety for the patient and the dentist. Orabloc® Iniettore Monouso is registered in Europe.**
- **ORABLOC® in Poland achieved a 24% increase in sales for the first seven months of 2015 compared to the same period of 2014.**

Capua, 2 September 2015 – **Pierrel Pharma S.r.l.** (the “**Company**”) – a wholly owned subsidiary of **Pierrel S.p.A.** dedicated to the development, registration and licensing of new drugs and medical devices – continues its mission to innovate products and services for professionals in the dental care sector, and has launched in Poland **Orabloc®** (Articaina by Pierrel) **iniettore monouso**.

Orabloc® iniettore monouso is the first and unique device with total safety for the patient and the dentist where it is necessary to use a dental anaesthetic. This is a single-use, single-dose injection kit, pre-charged with Articaina Pierrel, prepared to minimise the incidence of possible contamination from patient to patient. The device also has a simple mechanism that enables, once the drug has been injected, to handle the needle used in a safe manner, avoiding all contact with possible blood residue with the operator and with the surrounding environment.

It is noted that among the risky procedures that expose the operator to the risk of virus (Hepatitis C, for example) and/or bacterial contamination, there are the needlestick injuries when local anaesthetics are administered and during the recapping of the needle; 94% of health operators employed in dental studies report needlestick injuries (source: Klein study, 1988 in “I quaderni della professione” n°10 - Andi).

Orabloc® iniettore monouso, with an EU registration, will be available from November 2015 in Poland, being the first country to grant freedom to sell in its own country. In Poland, after all, **Orabloc®** in its traditional presentation in a vial is confirmed as a product with absolute reliability for dentists and achieved a **24% increase in sales among final users for the first seven months of 2015 compared to the same period of 2014**.

“Poland is an extraordinary market to start the global penetration of the new format for Orabloc”, stated Fabio Velotti, sole Director of Pierrel Pharma, who continued: “Very quickly when the necessary paper formalities are completed for the registration in France and Germany, the new device will also arrive in these European markets, together with the traditional product in vials. Our medium term plan is to register and sell the device in all countries where the Pierrel anaesthetics are already sold. The innovative content of Orabloc® iniettore monouso is evident: it comprises a simple device and at the same time has absolute safety for the patient and the operator. We are sure that it will contribute to further improving the excellent performance by Pierrel Pharma in the first half of 2015”.

Pierrel Pharma recorded sales of **€ 3.2 million in the first half of 2015i**, an increase of some **42%** compared to the **€ 2.2 million** recorded in the same period of 2014 and a positive **EBITDA of € 0.3 million**, which compared to a negative **EBITDA of some € 0.2 million** achieved at 30 June 2014. These results are mainly due to greater sales volumes of the dental anaesthetic **Orabloc®** achieved in the North American market.

Pierrel S.p.A. is a global supplier to the pharmaceutical, biopharmaceutical and life science industries, specialising in the discovery of medicinal product candidates and the repositioning of existing drugs for new therapeutic indications and



clinical research (TCRDO Division), pharmaceutical production (Contract Manufacturing Division) and the development, registration and licensing of new drugs and medical devices (Pharma Division).

Pierrel Group is listed on the MTA exchange which is organised and managed by Borsa Italiana and boasts over 60 years' experience in the pharmaceutical sector, being one of Europe's leading producers of local and dental anaesthetics. The TCRDO Division, working across Europe and the US, is recognised internationally for its research and development into tech based clinical research innovations with its Drug Repositioning and Repurposing System ("DRR2.0") and Integrated Clinical Development Services ("ICDS") for the pharmaceutical, biotechnology and biomedical industries. The parent company of the TCRDO Division (**THERAMetrics holding AG**, listed in the Swiss stock exchange) holds the innovative interactive **DRR2.0** platform, which runs on a database of 24 million scientific publications (being virtually all of those available in the field of biomedical literature), of over 4,900 drugs and of 9,400 illnesses. With this data, never before collected in one place and stored in the cloud, the Search and Match algorithm can show a researcher not only the candidate drug but also a detailed road map with indications of possible second medical uses. The database can be searched by molecule or by illness. Pierrel also has a production unit in Capua, close to Naples, Italy, that has been authorised by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for the aseptic production of injectable medicines. The subsidiary Pierrel Pharma S.r.l. has registered and distributes the Orabloc® dental anaesthetic in Canada, US, Russia and Europe.

The registered office of Pierrel S.p.A. is in Capua (CE), Italy.

For further information:

Pierrel S.p.A.

Investor Relations

Dr Raffaele Petrone

e-mail:

investor.relations@pierrelgroup.com

tel. +39 0823 626 111

fax +39 0823 626 228

Global Consult S.r.l.

Media Relations

Rossana Del Forno

e-mail:

areacomunicazione@globalconsultsrl.com

tel. +39 333 6178665